Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

High blood pressure, diabetes and stroke rates are higher in coastal or lakefront areas with greater concentrations of ...

The primary outcome was the time to the first ischaemic or haemorrhagic stroke after diabetes diagnosis, with follow-up until death or December 31, 2022. "These findings highlight the need for ...

Stroke is the leading cause of serious long-term disability and among the top five causes of death in the United States: more ...

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

The study concluded that treatment with SGLT-2I in conjunction with GLP-1RA may help to reduce the incidence of AF/flutter ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart or kidney disease.